RISK FOR SECOND PRIMARY MALIGNANCIES IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES RECEIVING BISPECIFIC ANTIBODIES: A REAL-WORLD ANALYSIS

G. PERIAPATTANAM[1], M. EYSHA[1], M. ASAD[1], A. CHEEMA[1] E. TURK[2] , A. ASAD[3], MB. ABID[4]

1. Texas Tech University Foster School of Medicine, El Paso, Texas, USA
2. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
3. University of Texas Medical Branch John Sealy School of Medicine, Galveston, TX, USA
4. Division of Hematology/Oncology, Texas Tech University Health Sciences Center, Lubbock, TX, USA

BACKGROUND

- Bispecific antibodies (BsAb) are universally available, off-the-shelf therapies that have demonstrated high efficacy in treating various hematologic malignancies and solid tumors
- Despite the therapeutic successes, long-term side effects, specifically the risk for second primary malignancies (SPMs), remain elusive
- This study leverages a large-scale, real-world database to evaluate the prevalence and types of SPMs

AIMS

- Use real-world clinical data to inform post-treatment surveillance for patients on Bispecific Antibody therapy
- Identify the most frequently observed SPM subtypes within the solid tumor and hematologic malignancy categories
- Determine the incidence of SPMs among adults with hematologic malignancies receiving Bispecific Antibody therapy

METHODS

- We conducted a retrospective cohort study using de-identified electronic health records from the TriNetX database
- Adults (≥18 years) diagnosed with hematologic malignancies between October 25, 2022, and January 25, 2026, were identified using ICD-10 codes
- The primary outcome was the development of SPMs, stratified into solid tumor (ST) and hematologic malignancies (HMs) categories
- Risk was calculated as incidence proportions within the cohort

CONCLUSIONS

- This large-scale, real-world analysis characterizes the incidence and distribution of SPMs in patients treated with Bispecific Antibody therapy
- The rates of SPMs highlight the critical relevance of these events in the post-treatment period and underscore the necessity for continued oncological surveillance

RESULTS

Category	Ethnicity								
Subcategory	Not Hispanic/Latino	Hispanic/Latino	Unknown						
Percentage (%)	64.54	15.00	20.46						
Category	**Race**								
Subcategory	White	Black/African American	Asian	American Indian	Native Hawaiian	Other	Unknown		
Percentage (%)	64.10	10.22	3.31	0.77	0.37	6.34	14.89		
Category	**Geographical Distribution**								
Subcategory	New England	Middle Atlantic	East North Central	West North Central	South Atlantic	East South Central	West South Central	Mountain	Pacific
Percentage (%)	5.00	21.00	11.00	7.00	14.00	2.00	8.00	7.00	14.00

CONTACT INFORMATION

Gaurav Periapattanam

gaperiap@ttep.edu

832-612-0629

REFERENCES

This report describes a Analyze Outcomes Analysis, named Bites Analysis Hematologic amlignancy (1), generated by the TriNetX platform on Jan 28, 2026, 01:58:02 UTC. This analysis describesthe outcomes for cohort BITES with 4,183 patients.